5th RSC / DMDG / DMG New Perspectives in DMPK
(Due to the ongoing issues surrounding COVID-19 and consideration of the safety of all, we have decided to switch this meeting to an online format, rather than a face-to-face one. The meeting will be delivered by a bespoke Virtual Venue (including auditorium, networking cafe, exhibitor rooms, poster room etc) and the organisers have an excellent record of running such meetings online during these challenging times and we would like to offer you the opportunity to join us online instead for what remains an outstanding programme!)”
Event
5th RSC / DMDG / DMG New Perspectives in DMPK
Dates
Tuesday-Wednesday, 22nd-23rd February 2022
Place
Virtual
Downloads and Links
First announcement
Abstract template – closing dates are 25th November (oral) and 13th January (poster)
DMPK – bursary application form – closing date is 7th January
Twitter hashtag – #DMPK22
Synopsis
Members from across the DMPK research community are encouraged to join colleagues from across academic, industrial, and third-sector institutions and contribute to the ongoing discussion, evolution and application of DMPK in various scenarios.
The event programme will incorporate sessions themed around the following key topics:
– DMPK and Drug Discovery
– DMPK and Drug Safety
– Analytical and Computational Advances in DMPK
In addition, the programme also includes a keynote talk, ‘flash’ presentations from early career researchers, and opportunities for open debate and discussion.
Programme Themes
Session 1 – DMPK and Drug Discovery
Understanding chemical and biological interactions that mediate pharmacological and toxicological effects of drugs and their metabolites is an important part of the drug discovery picture. In this session, we will showcase some of the more recent developments in our collective understanding.
Session 2 – DMPK and Drug Safety
This session will provide an interdisciplinary platform for academics and scientists to present and discuss the most recent innovations and practical challenges in the fields of DMPK to address drug safety, and particularly the emerging safety issues relating to biotherapeutics. It will include presentations on transporters associated with drug-induced tissue injury, new in vitro models for mechanistic toxicity assessment, and recent developments in predicting intrinsic immunogenicity of drugs.
Session 3 – Analytical and Computational Advances in DMPK
Advances in analytical and computational performance, and the availability of new instruments, methods, and approaches commonly unlocks new knowledge about compound stability, reactivity, interaction, and disposition. This session will showcase recent developments in bioanalytical science and computational modelling that have provided fresh insight and understanding in DMPK.
Who should attend
Medicinal chemists, drug discovery scientists, pharmacologists, toxicologists, DMPK scientists – from academia, industry, and third sector institutions.
Call for Abstracts
The call for both oral and poster abstracts is open, and the closing dates are 25th November (oral) and 13th January (poster). At the time of submission, poster presenters are asked whether they wish also to be considered for a short oral presentation.
To submit an abstract, please download and submit this template.
Programme
Tuesday, 22nd February
| 12.30 | Join meeting and networking in Virtual Coffee Bar |
|---|---|
| 13.00 | Welcome Toby Athersuch, Imperial College London, UK Joint Organising Committee (RSC-BMCS, DMDG, DMG) |
| 13.10 | Keynote presentation: Metabolism of strained rings: tales of the unexpected Martin Hayes, AstraZeneca, SE |
| Flash poster presentations Session Chair: Toby Athersuch, Imperial College London, UK |
|
| 14.00 | Microfluidic hemodynamic model of blood-brain barrier on a chip to study drug transport into the brain Gaurav Gupta, University of Nottingham, UK |
| 14.05 | Exploring the application of enzyme-linked microfluidic reactors to the synthesis of oxidised and conjugated human drug metabolites Huw S Jones, University of Bradford, UK |
| 14.10 | Presentation title to be confirmed (poster) Presenter to be confirmed |
| 14.15 | Bring-your-own coffee - exhibition, posters & networking |
| DMPK and Drug Discovery I – Chemistry and Mechanisms Session Chair: Mark Seymour, PharMAS Consulting, UK |
|
| 14.45 | “The secret life of glucuronides” Andrew Stachulski, University of Liverpool, UK |
| 15.25 | Preclinical DMPK applications of normothermic perfused whole porcine and cholestatic human livers Evita van der Steeg, TNO, The Netherlands |
| DMPK and Drug Discovery II – Application and Strategy Session Chair: Mark Seymour, PharMAS Consulting, UK |
|
| 16.05 | Is drug lipidation a new paradigm in DMPK? John Sanderson, Durham University, UK |
| 16.45 | Keynote presentation: Translational PKPD to guide drug discovery Piet H. van der Graaf, Senior Vice President, Certara & Professor of Systems Pharmacology Leiden University, The Netherlands |
| 17.25 | Close |
| 18.00 | Drinks reception |
| 19.00 | Conference dinner (optional) |
| 22.30 | Close |
Wednesday, 23rd February
| 08.30 | Join meeting and networking in Virtual Coffee Bar |
|---|---|
| Drug Discovery and Drug Safety | |
| 09.00 | Acyl glucuronides in perspective Ian Wilson, Imperial College London, UK |
| 09.40 | "The ADME and PKPD profile of an Ion Channel Blocker for a Hot Target" Dr Kevin Beaumont, AstraZeneca, Cambridge, UK |
| 10.20 | The Impact of Aldehyde Oxidase Mediated Metabolism in the Development of a Clinical Candidate, AWZ1066S, for the Treatment of Human Filariasis David Hong, University of Liverpool, UK |
| 11.00 | Bring-your-own coffee - exhibition, posters & networking |
| Analytical and Computational Advances in DMPK - Part 1 | |
| 11.20 | DILIsym Quantitative Systems Toxicology modelling – GSK experience Melanie Sakatis, GSK, UK |
| 12.00 | Predicting Reactivity in Drug Metabolism: Beyond CYPs Mario Oeren, Optibrium Ltd, UK |
| 12.40 | Optimising proteolysis targeting chimeras (PROTACs) for oral drug delivery: A drug metabolism and pharmacokinetics perspective Andy Pike, AstraZeneca Ltd, UK |
| 13.20 | Bring-your-own lunch - exhibition, posters & networking |
| Analytical and Computational Advances in DMPK - Part 2 | |
| 14.20 | Use of liver spheroids in a pharmaceutical hepatic safety strategy Dominic Williams, AstraZeneca, UK |
| 15.00 | One-stop metabolite shop: employing multiple tools for accessing drug metabolites Julia Shanu-Wilson, Hypha Discovery Ltd, UK |
| 15.40 | Finding the metabolite needle in a matrix haystack James O’Neill, Charles River Laboratories, UK |
| 16.20 | Closing remarks Toby Athersuch, Imperial College London, UK and Joint Organising Committee (RSC-BMCS, DMDG, DMG) |
| 16.30 | Close of meeting |
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.
Registration, Students, and Bursaries
Registrations are open and discounted rates are offered to members of the RSC, DMG and DMDG. Those registering before the early-bird deadline (31st January 2022) will be eligible for further reduced registration rates. A number of student/early career researcher bursaries are also available. If you are a member of the RSC or DMG, please use the voucher code provided by your membership organisation. If you are a DMDG member, then simply register in the usual way.
To register please click here
We are grateful to our supporter: EFMC
Our Sponsors
We are grateful to our confirmed sponsors for their valued support.
Organising Committee
Toby Athersuch (chairman), Imperial College London and the DMG
Xiaoli Meng, University of Liverpool
Dean Naisbitt, University of Liverpool
Mark Seymour, PharMAS Consulting and DMDG
Andrew Stachulski (treasurer), University of Liverpool and RSC-BMCS
Secretariat Contact and Further Information
Stuart Hex, DMDG, UK
+44 (0)116 274 7352
E-mail
